Business Context and Reporting Period
Company: NeoGenomics, Inc. (NEO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: NeoGenomics operates a network of cancer-focused testing laboratories in the U.S. and U.K., providing oncology diagnostic testing, molecular residual disease (MRD) testing, and pharmaceutical development services. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Revenue | $727.3 million | $660.6 million | +10.1% |
| Gross Profit | $314.3 million | $290.1 million | +8.3% |
| Gross Margin | 43.2% | 43.9% | -0.7 pts |
| Net Loss | $(108.0) million | $(78.7) million | -37.2% |
| Adjusted EBITDA | $43.4 million | $39.6 million | +9.5% |
| Cash from Operations | $5.2 million | $7.0 million | -25.7% |
| Cash & Equivalents (End of Period) | $159.6 million | $367.0 million | -56.5% |
| Long-Term Debt (Net) | $341.9 million | $340.3 million | +0.5% |
Note: Net Loss per share was $(0.84) for 2025 compared to $(0.62) for 2024.
Material Changes vs. Prior Period
- Revenue Growth: Driven by increased test volumes, a shift to higher-value tests, and the acquisition of Pathline LLC in April 2025. Growth was partially offset by lower non-clinical revenue due to macro clinical trial trends.
- Impairment Charges: The company recorded $27.8 million in impairment charges in 2025, compared to none in 2024. This included a $15.9 million charge related to the disposal of Trapelo Health assets and an $11.4 million charge for the InVisionFirst-Lung portfolio wind-down.
- Debt Repayment: The company repaid $201.3 million of 2025 Convertible Senior Notes in May 2025, significantly reducing interest expense ($3.8 million in 2025 vs. $6.6 million in 2024).
- Operating Expenses: General and Administrative expenses increased by $13.6 million, primarily due to higher compensation costs and technology investments. Restructuring charges were eliminated in 2025 following the completion of the program in 2024.
Guidance, Outlook, and Risks
Management Outlook
Management expects to sustain growth through targeted innovation in therapy selection and MRD testing. The 2026 focus includes expanding into the community oncology market and optimizing operational efficiency through automation. Capital expenditures for 2026 are forecasted to range between $30 million and $35 million.
Key Risks and Contingencies
- Regulatory Investigation: The company is under ongoing review by the Office of Inspector General (OIG) regarding compliance with federal healthcare laws. A reserve of $11.2 million has been accrued for potential damages, though the company cannot estimate losses beyond this amount.
- Legal Proceedings: Patent litigation with Natera regarding the RaDaR test was resolved in December 2025 with no remaining claims. A shareholder class action (Goldenberg Matter) remains pending.
- Liquidity: Cash and cash equivalents decreased significantly to $159.6 million due to debt repayment and investing activities. Management believes current cash is sufficient for operations for at least the next 12 months.
- Goodwill Impairment Risk: While no goodwill impairment was recorded in 2025, the company noted indicators of potential impairment in Q3 2025 before a quantitative test showed fair value exceeded carrying value. Future declines in operating results could trigger impairment charges.
Investor Verification Checklist
- Regulatory Reserve Adequacy: Verify if the $11.2 million reserve for the OIG investigation is sufficient given the ongoing nature of the review.
- Debt Maturity Profile: Confirm the terms and conversion triggers for the remaining $345 million in 2028 Convertible Senior Notes.
- Impairment Triggers: Monitor future quarterly results for indicators that could trigger goodwill or intangible asset impairments, given the $27.8 million charge in 2025.
- Cash Burn vs. Revenue Growth: Assess the sustainability of the 10.1% revenue growth against the decline in operating cash flow and the significant reduction in cash reserves.
- Pathline Integration: Evaluate the financial performance of the Pathline acquisition ($13.1 million revenue, $5.8 million net loss in 2025) to ensure it meets strategic synergy goals.